Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2426 - 2450 of 3616 in total
Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered...
Investigational
Investigational
Matched Iupac: … 9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-14-yl]oxy}oxane-2-carboxylic acid ... (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-{[(1S,5R,13R,14S,17R)-10-hydroxy-4-methyl-12-oxa-4-azapentacyclo[ …
Experimental
Matched Products: … FERLOS 20 MG/ML ORAL ÇÖZELTİ, 10 ADET ... VEGAFERON 100 MG/5 ML ORAL ÇÖZELTİ, 10 ADET ... FERTAMİR 40 MG EFERVESAN GRANÜL İÇEREN SAŞE, 10 SAŞE …
KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased potency, favorable tissue distribution, and ease of formulation.
Investigational
Investigational
PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.
Investigational
Matched Products: … ทานาทริล 10 มก. ชนิดเม็ด ... TANATRIL TABLETS 10 mg …
Investigational
Investigational
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Experimental
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is being developed by Amira.
Investigational
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
Investigational
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
Investigational
Matched Iupac: … 5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1^{2,10}.0^{3,8}.0^{4,25}.0^{19,27}.0^{21,26 ... }.0^{14,28}]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione …
MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).
Investigational
Thioglycolic acid is under investigation in clinical trial NCT03238105 (Treatment of Periorbicular Hyperchromia Comparing 10% Thioglycolic Acid Peeling Versus Pulsed Intense Light).
Investigational
Matched Description: … under investigation in clinical trial NCT03238105 (Treatment of Periorbicular Hyperchromia Comparing 10% …
Investigational
Investigational
Investigational
QR-313 is an antisense oligonucleotide targeting exon 73. It is being investigated for the treatment of dystrophic epidermolysis bullosa.
Investigational
Investigational
Experimental
Displaying drugs 2426 - 2450 of 3616 in total